Erika Hamilton, MD, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, discusses the results of the EMERALD study (NCT03778931), a randomized, open-label, Phase III trial evaluating the efficacy and safety of elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigators choice of endocrine therapy for patients with ER+/HER2- advanced breast cancer following CDK46 inhibitor therapy. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

свернуть